Business
Bioasis Announces Filing of Its Quarterly Financial Statements and MD&A for the Period Ending August 31, 2018
Bioasis Announces Filing of Its Quarterly Financial Statements and MD&A for the Period Ending August 31, 2018.
About this update from Bioasis Technologies Inc.
[{"type":"text","content":"\n \n BIOASIS \n TECHNOLOGIES INC. (OTCQB:BIOAF; TSX.V:BTI), a biopharmaceutical \n company developing its xB3 TM proprietary platform technology \n for the delivery of therapeutics across the blood-brain barrier (BBB) \n and the treatment of CNS disorders in areas of high unmet medical need, \n including brain cancers and neurodegenerative diseases, today announced \n that it has filed its unaudited quarterly financial statements and \n management’s discussion and analysis for the period ended Aug. 31, 2018. \n All are available under the Company's profile on SEDAR at www.sedar.com \n and on the Company's website at www.bioasis.us/investors/.\n \n \n Bioasis also announces that Christopher Lowe, M.B.A., of FLG \n Partners, who has served as the Company’s chief financial officer \n (CFO) since Oct. 2, 2017, has resigned. We thank Chris and FLG Partners \n for their diligence and effective oversight of the Company. The Company \n is in the process of identifying a replacement CFO and Mark Day, Ph.D., \n director, president and chief executive officer, will serve as interim \n CFO. With Mr. Lowe’s departure, the Company has retained a public \n accounting and advisory services firm, which will be better able to \n locally support Bioasis in Connecticut, to provide accounting and \n bookkeeping services. Manning Elliot continues to be the Company’s \n auditor.\n \n \n On behalf of the Board of Directors of Bioasis Technologies Inc.\n \n \n Mark Day, Ph.D., Director and President & Chief Executive Officer\n \n \n About Bioasis\n \n \n Bioasis \n Technologies Inc. is a biopharmaceutical company developing the xB3 \n TM platform, a proprietary technology for the delivery of \n therapeutics across the blood-brain barrier (BBB) and the treatment of \n CNS disorders in areas of high unmet medical need, including brain \n cancers and neurodegenerative diseases. The delivery of therapeutics \n across the BBB represents the final frontier in treating neurological \n disorders. The in-house development programs at Bioasis are designed to \n develop symptomatic and disease-modifying treatments for brain-related \n diseases and disorders. The company maintains headquarters in Guilford, \n Conn., United States. Bioasis trades on the TSX Venture Exchange under \n the symbol “BTI” a...